Search Results - "Lustig, Tzipi"

BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study by Borthakur, Gautam, Ofran, Yishai, Tallman, Martin S., Foran, James, Uy, Geoffrey L., DiPersio, John F., Showel, Margaret M., Shimoni, Avichai, Nagler, Arnon, Rowe, Jacob M., Altman, Jessica K., Abraham, Michal, Peled, Amnon, Shaw, Stephen, Bohana‐Kashtan, Osnat, Sorani, Ella, Pereg, Yaron, Foley‐Comer, Adam, Oberkovitz, Galia, Lustig, Tzipi M., Glicko‐Kabir, Irit, Aharon, Arnon, Vainstein‐Haras, Abi, Kadosh, Shaul E., Samara, Emil, Al‐Rawi, Ahmed N., Pemmaraju, Naveen, Bueso‐Ramos, Carlos, Cortes, Jorge E., Andreeff, Michael

“…Background CXCR4 mediates the retention and survival of acute myelogenous leukemia blasts in bone marrow and contributes to their resistance to chemotherapy…”
Get full text

Use of Combination Premedication Prior to Motixafortide Administration Reduced Severity and Frequency of AEs in the Phase 3 Genesis Trial - a Single Center Analysis by Crees, Zachary David, Stockerl-Goldstein, Keith, Schroeder, Mark A., Vij, Ravi, Sorani, Ella, Gliko Kabir, Irit, Goldstein, Inbal, Lustig, Tzipi, Kadosh, Shaul, DiPersio, John F.

“…Background: Motixafortide is a novel, high affinity CXCR4 antagonist with extended receptor occupancy that facilitates the migration of hematopoietic stem and…”
Get full text

The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia by Borthakur, Gautam, Tallman, Martin S., Ofran, Yishai, Foran, James M., Uy, Geoffrey L, DiPersio, John F, Nagler, Arnon, Rowe, Jacob M., Showel, Margaret M., Altman, Jessica, Al-Rawi, Ahmed, Wang, Rui-Yu, Peled, Amnon, Abraham, Michal, Pereg, Yaron, Vainstein, Abi, Oberkovitz, Galia, Lustig, Tzipi, Aharon, Arnon, Bueso-Ramos, Carlos E., Cortes, Jorge E., Andreeff, Michael

“…▪ Background: Persistence of minimal residual disease (MRD) after induction, consolidation and salvage therapies is an independent poor prognostic marker in…”
Get full text

Final Phase IIa Study Results Evaluating the CXCR4 Antagonist BL-8040 in Combination with Cytarabine (Ara-C) for the Treatment of Relapsed/Refractory AML Patients by Borthakur, Gautam, Tallman, Martin, Ofran, Yishai, Foran, James, Uy, Geoffrey, DiPersio, John, Nagler, Arnon, Rowe, Jacob, Showel, Margaret, Altman, Jessica, Peled, Amnon, Abraham, Michal, Pereg, Yaron, Vainstein, Abi, Oberkovitz, Galia, Lustig, Tzipi, Aharon, Arnon, Bueso-Ramos, Carlos, Cortes, Jorge, Andreeff, Michael

Get full text